---
title: "Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286499271.md"
description: "TD Cowen analyst Ritu Baral has reaffirmed a Buy rating on Benitec Biopharma (BNTC) due to its strong financial position and clear clinical development path for BB-301. With approximately $185M in cash expected to fund ongoing studies into 2028, the company is well-positioned to reduce financing risks. The advancing clinical strategy and planned FDA meeting in mid-2026 further support the stock's potential, with Evercore ISI also initiating coverage with a Buy rating and a $25 price target."
datetime: "2026-05-15T02:55:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286499271.md)
  - [en](https://longbridge.com/en/news/286499271.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286499271.md)
generator: "portal-rs"
---

# Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia

TD Cowen analyst Ritu Baral has maintained their bullish stance on BNTC stock, giving a Buy rating on May 12.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Ritu Baral has given his Buy rating due to a combination of factors, including Benitec Biopharma’s solid financial position and clear clinical development path for BB-301. The company’s approximately $185M cash balance, with an expected runway into 2028, is projected to fully fund the ongoing Phase 1b/2a study and the planned pivotal program, reducing near-term financing risk and supporting continued execution.

Ritu Baral’s rating is based on confidence in BB-301’s clinical strategy and regulatory alignment in OPMD dysphagia. The advancing dose-escalation study, early safety confirmation enabling higher-dose Cohort 2, and the plan to meet the FDA in mid-2026 to finalize a pivotal trial design using a proprietary responder index collectively support the therapeutic’s potential and create a clear value-inflection timeline into the 2H26 data readout and beyond.

In another report released on May 12, Evercore ISI also initiated coverage with a Buy rating on the stock with a $25.00 price target.

### Related Stocks

- [BNTC.US](https://longbridge.com/en/quote/BNTC.US.md)
- [EVR.US](https://longbridge.com/en/quote/EVR.US.md)

## Related News & Research

- [Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Moderate Buy" from Analysts](https://longbridge.com/en/news/296672427.md)
- [Benitec Biopharma's (BNTC) "Buy" Rating Reaffirmed at HC Wainwright](https://longbridge.com/en/news/278425413.md)
- [Alliance Global Partners Reaffirms Their Buy Rating on Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/296781912.md)
- [Maxim Group Reaffirms Their Buy Rating on Our Bond Inc (OBAI)](https://longbridge.com/en/news/296798454.md)
- [Scotiabank Sticks to Its Buy Rating for Movida Participacoes SA (MOVI3)](https://longbridge.com/en/news/296795664.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**